

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 27 February 2018

Release: Immediate

Topic: Release of Financial Results for Half-Year ended 31 December 2017



Highlights:

- **Record sales revenue of A\$38 million for the half achieved as Ellex's glaucoma market penetration strategy gains traction**
- **Revenue and earnings in line with previous trading update**
- **Cash balance of A\$25 million - Ellex well capitalised to grow top line revenue through glaucoma focus**
- **65% uplift in USA sales of lead product Ellex iTrack™ and 9% lift in Core Laser and Ultrasound business sales resulted in 12% growth in Group sales compared with the prior corresponding period**
- **Revenue expected to continue to increase in the second half**

Adelaide, Australia 27 February 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today released its audited financial results for the half-year ended 31 December 2017.

Performance and Strategy

During the period, Ellex continued to invest capital in the glaucoma market penetration strategy, primarily for its consumable Ellex iTrack™ catheter. Ellex iTrack™ is used in a minimally invasive ocular surgery technique to reduce eye pressure by dilating and flushing the natural outflow systems to reduce or eliminate the need for eye drops.

Ellex's first half sales revenue of A\$38 million was driven by sales of its glaucoma treatment lasers ("SLT") and the Ellex iTrack™ device. The direct result of this investment was shown by the improvement in revenue, for both the Ellex SLT lasers and the Ellex iTrack™ catheters. These devices together target the broadest spectrum of glaucoma patient profiles with a minimally invasive glaucoma surgery (MIGS) approach. Ellex is the only company to offer this synergy in restorative glaucoma treatments, equipping it with a considerable market advantage.

Revenue from sales in the USA of Ellex iTrack™ was up 65% on the prior corresponding period and this, along with a 9% lift in revenue from the Core Laser and Ultrasound business, underpinned group revenue growth of 12% (13% in constant currency). Importantly, this trend in material improvement in group revenue is expected to continue into the second half.

Ellex raised A\$23 million from US and Australian institutions in the second quarter of the current fiscal year to support its glaucoma market penetration strategy. Specifically, this capital has been, and will continue to be, primarily directed to the Ellex iTrack™ business in the USA to support the following initiatives:

- Significant expansion of the Company's US Fremont manufacturing facility to accommodate growth in product sales
- Appointment of additional field sales representatives, and regional sales management personnel
- Expanded physician key opinion leader recruitment and engagement
- Enhanced tradeshow infrastructure equipped with tactile surgical simulators
- Improved clinical training program and selling tools

The Company has a strong balance sheet position. As of 31 December 2017, the Company had A\$25.2 million of cash, trade borrowings of A\$8.5 million and bank debt on its Mawson Lakes (Australia) and production facility of A\$6.9 million.

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information please contact:

Tom Spurling, Chief Executive Officer
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Mark Lindh, Investor Relations & Corporate
W +61 8 87074 8200 | M +61 414 551 361
mlindh@ellex.com

CONSOLIDATED RESULTS FOR ANNOUNCEMENT TO THE MARKET

For the half year ended 31 December 2017 Ellex Medical Lasers Limited ACN 007 702 927

This results announcement and the half-year report attached to this announcement should be read in conjunction with the annual financial report for the year ended 30 June 2017.

Current reporting period: Half-year ended 31 December 2017

Previous corresponding reporting period: Half-year ended 31 December 2016

Consolidated Results

				\$A'000
Revenues from ordinary activities	Up	12%	To	38,243
Consolidated results				
(Loss) before interest, tax, depreciation and amortisation (EBITDA)	Down	126%	to	(816)
(Loss) for the period, before tax	Down	278%	to	(2,705)
(Loss) from ordinary activities after tax	Down	343%	to	(2,440)
Net (loss) for the period attributable to members	Down	343%	to	(2,440)

Dividends (distributions)	Amount per security	Franked amount per security
Final Dividend	Nil	Nil
Interim Dividend		
Previous corresponding period	Nil	Nil
Record date for determining entitlements to the dividend	NOT APPLICABLE	

OTHER INFORMATION

For the half-year ended 31 December 2017
Ellex Medical Lasers Limited ACN 007 702 927

Net Tangible Assets per Security	Half Year ended 31 December 2017	Half Year ended 31 December 2016
Net tangible asset backing per ordinary security (excludes value attributable to goodwill, other intangible assets, deferred tax asset, capitalised development expenditure and related deferred grant income)	\$0.37	\$0.31

Dividends

Date the dividend (distribution) is payable

NOT APPLICABLE

Record date to determine entitlements to the dividend
(distribution)

NOT APPLICABLE

If it is a final dividend, has it been declared?

NOT APPLICABLE

Amount per security

	Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
Final dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢
Interim dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢

Details of entities over which control has been gained or lost during the period

The group has not gained or lost control over any entities during the half-year ended 31 December 2017.

Ellex Medical Lasers Limited

ACN 007 702 927

Report for the half-year ended 31 December 2017

Contents

Page

Directors' report	2
Auditor's independence declaration	4
Consolidated statement of profit or loss and other comprehensive income	5
Consolidated statement of financial position	6
Consolidated statement of changes in equity	7
Consolidated statement of cash flows	8
Notes to the consolidated financial statements	9
Directors' declaration	13
Independent auditor's review report	14
Corporate directory	16

Directors' report

The directors of Ellex Medical Lasers Limited (the Company and the Group) submit herewith the financial report of Ellex Medical Lasers Limited and its subsidiaries (the Group) for the half-year ended 31 December 2017. In order to comply with the provisions of the Corporations Act 2001, the directors report as follows:

The names of the directors of the Company during or since the end of the half-year are:

Name

Mr V Previn	Chairman
Mr A Sundich	Non-Executive Director
Mr G Canala	Non-Executive Director
Mr Rahmon Coupe	Independent Director
Dr Meera Verma	Executive Director
Ms Maria Maieli	Company Secretary

Principal Activities

The principal activities of the Company during the financial period were the manufacture, service and distribution of medical equipment.

There were no significant changes in the nature of the activities of the company during the period.

Review of operations

Ellex Medical Lasers Limited (Ellex) generated a Net Loss after Tax of \$2,440 thousand for the half-year ended 31 December 2017 (2016: a Net Profit After Tax of \$1,004 thousand) on revenue of \$38,243 thousand (2016: \$34,259 thousand). The increase in the loss in the current reporting period compared with the same time last year is a direct result of the Company's strategic decision to invest in sales and marketing infrastructure for the Ellex iTrack business segment and the glaucoma business in general.

Group

The Company's strategy to focus on glaucoma therapy devices achieved traction during the period, with Ellex recording strong sales revenue for the first-half. Revenues from glaucoma therapy devices were A\$19.8 million in the first-half and have grown at a CAGR of 16% over the last four periods.

Ellex will continue to exploit its unique combination treatment offering of glaucoma treatment lasers ("SLT") and Ellex iTrack™ minimally invasive glaucoma surgery (MIGS) device in the fast-growing glaucoma therapy market.

Ellex iTrack

Sales revenue in the USA of the Ellex iTrack™ MIGS device grew by 65% to US\$2.5 million during the period, up from US\$1.5 million in the prior corresponding period. This growth was achieved as a result of the Company's initial expansion of sales and marketing efforts in the USA. Outside the USA, sales grew by 30% to US\$1.6 million, up from US\$1.2 million in the prior corresponding period. This can be attributed to improved sales demand in existing European markets, and as a result of improved distribution management throughout the region. Gross margin on sales also improved, reflecting increased volume through the Fremont production facility.

The investment in our sales and marketing effort in the USA will continue.

Ellex Core Laser & Ultrasound

Driven by a 35% lift in sales for SLT lasers, the Company's Core Laser & Ultrasound sales grew by 8% (9% in constant currency) to A\$32.8 million, up from A\$30.4 million in the prior corresponding period. A concerted effort to reduce inventory by A\$2.1 million also generated strong cash flow during the period.

As foreshadowed in November 2017, Ellex undertook significant investments in sales and marketing, product management and additional management. Whilst these initiatives contributed to strong top-line sales growth of the Company's SLT laser portfolio, they resulted in a reduction of EBITDA to A\$3.5 million during the period, down from A\$4.3 million in the prior corresponding period.

Auditor's independence declaration

The auditor's independence declaration is included on page 4 of the half-year report.

Rounding of amounts

The company is a company of the kind referred to in ASIC Instrument 2016/191. In accordance with that Class Order amounts in the directors' report and the half-year financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Signed in accordance with a resolution of directors made pursuant to s.306 (3) of the Corporations Act 2001.

On behalf of the Directors

A handwritten signature in black ink, appearing to read 'V. Previn', is written over a light grey horizontal line.

Victor Previn
Chairman
Adelaide, 26 February 2018

Grant Thornton House
Level 3
170 Frome Street
Adelaide, SA 5000
Correspondence to:
GPO Box 1270
Adelaide SA 5001

T 61 8 8372 6666
F 61 8 8372 6677
E info.sa@au.gt.com
W www.grantthornton.com.au

Auditor's Independence Declaration To the Directors of Ellex Medical Lasers Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of Ellex Medical Lasers Limited for the half-year ended 31 December 2017. I declare that, to the best of my knowledge and belief, there have been:

- a No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b No contraventions of any applicable code of professional conduct in relation to the review.



GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



J L Humphrey
Partner – Audit & Assurance

Adelaide, 26 February 2018

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

Consolidated statement of profit or loss and other comprehensive income for the half-year ended 31 December 2017

		Consolidated Group	
		Half-year ended 31 Dec 2017 \$'000	Half-year ended 31 Dec 2016 \$'000
Revenue		38,243	34,259
Other income		143	679
Changes in inventories of finished goods and work in progress		(925)	4,696
Raw materials and consumables used		(18,075)	(18,881)
Employee benefits expense		(11,608)	(11,329)
Depreciation and amortisation expense		(1,704)	(1,406)
Facilities expense		(1,086)	(967)
Legal expenses		(84)	(100)
Advertising and marketing expense		(1,595)	(1,132)
Congress expenses		(889)	(824)
Finance costs		(185)	(157)
Implied interest for deferred consideration		-	(68)
Product development raw materials and consumables used		(452)	(536)
Realised foreign exchange (loss)/gain		(221)	202
Other expenses	12	(4,267)	(2,914)
(Loss)/profit before tax		(2,705)	1,522
Income tax benefit/(expense)		265	(518)
(Loss)/profit for the period		(2,440)	1,004
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange differences on translating foreign operations (tax: nil)		120	(92)
Total comprehensive (loss)/income for the period		(2,320)	912
Earnings per share:			
From continuing operations:			
Basic (cents per share)		(1.95)	0.87
Diluted (cents per share)		(1.95)	0.87

Notes to the consolidated financial statements are included on pages 9 to 12.

**Consolidated statement of financial position
as at 31 December 2017**

			Consolidated Group	
	Note	31 December 2017 \$'000	30 June 2017 \$'000	
Current assets				
Cash and cash equivalents		25,195	9,244	
Trade and other receivables		16,100	15,121	
Inventories		22,307	23,416	
Other current assets		1,184	911	
Total current assets		64,786	48,692	
Non-current assets				
Trade and other receivables		428	236	
Inventories		420	530	
Property, plant and equipment		14,397	13,452	
Intangible assets		3,789	3,879	
Capitalised development expenditure		14,257	13,446	
Deferred tax assets		7,254	6,307	
Total non-current assets		40,545	37,850	
Total assets		105,331	86,542	
Current liabilities				
Trade and other payables		7,554	9,016	
Borrowings	9	9,086	15,536	
Provisions		3,018	2,725	
Deferred income		1,083	907	
Current tax liabilities		64	137	
Total current liabilities		20,805	28,321	
Non-current liabilities				
Borrowings	9	6,360	99	
Provisions		444	450	
Deferred income		713	739	
Total non-current liabilities		7,517	1,288	
Total liabilities		28,322	29,609	
Net assets		77,009	56,933	
Equity				
Issued capital	10	78,345	55,949	
Reserves		(561)	(681)	
Accumulated (losses)/profit		(775)	1,665	
Total equity		77,009	56,933	

Notes to the consolidated financial statements are included on pages 9 to 12.

**Consolidated statement of changes in equity
for the half-year ended 31 December 2017**

	Issued capital \$'000	Other reserve \$'000	Foreign currency reserve \$'000	Accumulated profits/ (losses) \$'000	Total \$'000
Balance at 1 July 2016	46,041	142	(485)	2,559	48,257
Issue of share capital	10,290	-	-	-	10,290
Transaction costs	(382)	-	-	-	(382)
Total of transactions with owners	9,908	-	-	-	9,908
Profit for the period	-	-	-	1,004	1,004
Other comprehensive income	-	-	(92)	-	(92)
Total comprehensive income	-	-	(92)	1,004	912
Balance at 31 December 2016	55,949	142	(577)	3,563	59,077
Balance at 1 July 2017	55,949	142	(823)	1,665	56,933
Issue of share capital	23,577	-	-	-	23,577
Transaction costs	(1,181)	-	-	-	(1,181)
Total of transactions with owners	22,396	-	-	-	22,396
(Loss) for the period	-	-	-	(2,440)	(2,440)
Other comprehensive income	-	-	120	-	120
Total comprehensive income	-	-	120	(2,440)	(2,320)
Balance at 31 December 2017	78,345	142	(703)	(775)	77,009

Notes to the consolidated financial statements are included on pages 9 to 12.

Consolidated statement of cash flows for the half-year ended 31 December 2017

		Consolidated Group	
Note	Half-year ended 31 Dec 2017 \$'000	Half-year ended 31 Dec 2016 \$'000	
Cash flows from operating activities			
	42,416	39,769	
	(42,674)	(39,923)	
	(182)	(157)	
	(60)	(39)	
	(500)	(350)	
Cash flows from investing activities			
	42	39	
	(1,927)	(398)	
	(32)	(2,415)	
	(1,625)	(507)	
	12	2	
	(143)	(83)	
	(1,553)	(1,702)	
	(5,226)	(5,064)	
Cash flows from financing activities			
	23,577	10,290	
	(1,689)	(546)	
	893	2,697	
	(51)	(104)	
	(200)	-	
	(52)	(54)	
	22,478	12,283	
	16,752	6,869	
	8,456	7,283	11
	(13)	(6)	
	25,195	14,146	

Notes to the consolidated financial statements are included on pages 9 to 12.

Notes to the Consolidated financial statements for the half-year ended 31 December 2017

Note 1: Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2017 have been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standards including AASB 134: Interim Financial Reporting. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards.

Note 2: General information and basis of preparation

The condensed interim consolidated financial statements ('the interim financial statements') of the Group are for the six months ended 31 December 2017 and are presented in Australian Dollars, which is the functional currency of the Parent Company. These general purpose interim financial statements have been prepared in accordance with the requirements of the Corporations Act 2001 and AASB 134 Interim Financial Reporting. They do not include all of the information required in the annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2017 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Securities Exchange Listing Rules and the Corporations Act 2001.

The interim financial statements have been approved and authorised for issue by the Board of Directors on 26 February 2018.

Note 3: Significant accounting policies

The interim financial statements have been prepared in accordance with the same accounting policies adopted in the Group's last annual financial statements for the year ended 30 June 2017.

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these interim financial statements.

Note 4: Estimates

When preparing the interim financial statements, management undertakes a number of judgments, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgments, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgments, estimates and assumptions applied in the interim financial statements, including the key source of estimate uncertainty were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2017.

Note 5: Commitments

There is no commitment for the purchase of property, plant and equipment at 31 December 2017.

There are no other changes to the commitments disclosed at 30 June 2017.

Note 6: Contingencies

There has been no change in contingent liabilities since the last annual reporting period.

Note 7: Events occurring after the interim period

No matters or circumstances have arisen since the end of the half year which significantly affected or could significantly affect the operations, of the Group, the results of the operations or the state of affairs of the Group in the future financial years.

Note 8: Operating Segments

(i) Segment performance

	Lasers & Ultrasounds \$'000	2RT \$'000	iTrack \$'000	Total \$'000
Six months ended 31 December 2017				
Revenue				
External sales	32,825	197	5,221	38,243
Total segment revenue	32,825	197	5,221	38,243
Segment EBITDA	3,470	(414)	(2,188)	868
Depreciation and amortisation	(1,219)	(9)	(476)	(1,704)
Segment results	2,251	(423)	(2,664)	(836)
<i>Reconciliation of segment result to group net profit before tax</i>				
Unallocated items:				
• Corporate costs, quality and service charges				(1,809)
• Finance costs				(185)
• Interest and other revenue				125
Net (loss) before tax from continuing operations				(2,705)
Six months ended 31 December 2016				
Revenue				
External sales	30,386	236	3,637	34,259
Total segment revenue	30,386	236	3,637	34,259
Segment EBITDA	4,315	(400)	477	4,392
Depreciation and amortisation	(1,011)	(6)	(389)	(1,406)
Segment results	3,304	(406)	88	2,986
<i>Reconciliation of segment result to group net profit before tax</i>				
Unallocated items:				
• Corporate costs, quality and service charges				(1,861)
• Finance costs				(157)
• Interest and other revenue				554
Net profit before tax from continuing operations				1,522

Note 8: Operating Segments (Cont)

(ii) Segment assets

	Lasers & Ultrasounds \$'000	2RT \$'000	iTrack \$'000	Total \$'000
31 December 2017				
Segment assets - opening	57,970	3,206	9,815	70,991
Segment asset changes for the period:				
• Increase/(reduction) in assets	2,865	(105)	(869)	1,891
Total segment assets	60,835	3,101	8,946	72,882
<i>Reconciliation of segment assets to group assets</i>				
Inter-segment eliminations				
Unallocated assets:				
• Deferred tax assets and current tax asset				7,254
• Cash and cash equivalents				25,195
Total group assets				105,331
30 June 2017				
Segment assets – opening	51,316	2,480	6,109	59,905
Segment asset changes for the period:				
• Increase/(reduction) in assets	6,654	726	3,706	11,086
Total segment assets	57,970	3,206	9,815	70,991
<i>Reconciliation of segment assets to group assets</i>				
Inter-segment eliminations				
Unallocated assets:				
• Deferred tax assets & current tax asset				6,307
• Cash and cash equivalents				9,244
Total group assets				86,542

Note 9: Borrowings

Borrowings were classified as current at 30 June 2017 due to breaching the interest cover ratio. There is no breach of covenants at 31 December 2017 and borrowings are classified according to the banking agreement with ANZ.

Note 10: Issued capital

22,454,241 fully paid ordinary shares were issued at \$1.05 which saw an increase in issued capital. Associated capital raise costs have been recognised as a reduction in equity.

	31 December 2017		30 June 2017	
	No. '000	\$'000	No. '000	\$'000
Fully paid ordinary shares				
Balance at beginning of financial year	121,146	55,949	114,146	46,041
Share issue	22,455	23,577	7,000	10,290
Transaction costs for share issue	-	(1,689)	-	(545)
Tax impact of share issue costs	-	508	-	163
	143,601	78,345	121,146	55,949

Note 11: Reconciliation of cash and cash equivalents

	Half-year ended 31 Dec 2017 \$'000	Year ended 30 June 2017 \$'000
Cash and cash equivalents	25,195	9,244
Bank overdraft	-	(788)
	25,195	8,456

Note 12: Other expenses

	Half-year ended 31 Dec 2017 \$'000	Half-year ended 31 Dec 2016 \$'000
Consulting fees	845	422
Travel expenses	1,835	1,223
Other expenses	1,587	1,269
	4,267	2,914

Directors' declaration

The directors declare that:

- (a) The financial statements and notes are in accordance with the corporations Act 2001, including:
 - (i) complying with Accounting Standard 134 Interim Financial Reporting; and
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and of its performance for the half-year ended on that date.
- (b) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and

Signed in accordance with a resolution of the directors made pursuant to s.303 (5) of the Corporations Act 2001.

On behalf of the Directors

A handwritten signature in black ink, appearing to read 'V. Previn', with a horizontal line extending to the right.

Victor Previn
Chairman

Adelaide, 26 February 2018

Grant Thornton House
Level 3
170 Frome Street
Adelaide, SA 5000
Correspondence to:
GPO Box 1270
Adelaide SA 5001

T 61 8 8372 6666
F 61 8 8372 6677
E info.sa@au.gt.com
W www.grantthornton.com.au

Independent Auditor's Review Report To the Members of Ellex Medical Lasers Limited

Report on the Half Year Financial Report

Conclusion

We have reviewed the accompanying half year financial report of Ellex Medical Lasers Limited (the Group), which comprises the consolidated statement of financial position as at 31 December 2017, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, nothing has come to our attention that causes us to believe that the half year financial report of Ellex Medical Lasers Limited does not give a true and fair view of the financial position of the Ellex Medical Lasers Limited as at 31 December 2017, and of its financial performance and its cash flows for the half year ended on that date, in accordance with the *Corporations Act 2001*, including complying with Accounting Standard AASB 134 *Interim Financial reporting*.

Directors Responsibility for the Half Year Financial Report

The Directors of Ellex Medical Lasers Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2017 and its performance for the half year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Ellex Medical Lasers Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.



GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



J L Humphrey
Partner – Audit & Assurance

Adelaide, 26 February 2018

Corporate directory

Directors

Mr Victor Previn	BE (Chairman)
Mr Alex Sundich	BEd, MComm, ACA, FFINSIA (Non-Executive Director)
Mr Giuseppe Canala	BTECH, BA, FAICD (Non-Executive Director)
Mr Rahmon Coupe	BEng (Hons) (Independent Director)
Dr Meera Verma	PhD, FTSE, FAICD (Executive Director)

Company Secretary

Ms Maria Maieli	MPAcc, CPA
-----------------	------------

Registered Office

Ellex Medical Lasers Limited
ABN 15 007 702 927
3 Second Avenue
Mawson Lakes, South Australia 5095
Telephone: +61 8 7074 8200
Facsimile: +61 8 7074 8231

Auditors

Grant Thornton Audit Pty Limited
Level 13, 170 Frome Street
Adelaide South Australia 5000

Share Registry

Computershare Investor Services Limited
Level 5, 115 Grenfell Street
Adelaide, South Australia, 5000

GPO Box 1903
Adelaide, South Australia, 5001

Enquiries within Australia: 1300 556 161
Enquiries outside Australia: +61 3 9415 4000
Website: www.computershare.com

Websites:

www.ellex.com
www.slt-ellex.com

Stock Exchange

The company Ellex Medical Lasers Limited is listed on the Australian Securities Exchange (ASX).
The ASX Code is: ELX-Ordinary Shares.